LiPlaCis (liposomal cisplatin)

P1/2 | N=50 | NCT01861496 | Sponsor: Allarity Therapeutics | "Allarity Therapeutics, Inc...announced the results of a prospective Phase 2 clinical study of the Company’s proprietary DRP® technology that will be presented in a poster at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023....Data from the poster presentation will show that the cisplatin-DRP^® identified all four mBC patients who demonstrated a partial response (PR) in the trial as likely responders to the LiPlaCis™ treatment regimen using a DRP80+ score as a cut-off for likely responders. In addition, the cisplatin-DRP^® also identified mBC patients demonstrating other efficacy signals, including improved progression-free survival. Based on these data, researchers concluded that the cisplatin-DRP^® companion diagnostic can differentiate, in a statistically significant way, clinical responders and non-responders to cisplatin administered as LiPlaCis™."

"Allarity Therapeutics, Inc...announced that an abstract on the Company’s proprietary DRP^® technology has been accepted for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting....The poster shows the final data from a phase 2 study evaluating the ability of the DRP^® companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that are likely to respond to treatment with LiPlaCis^®, a targeted liposomal formulation of cisplatin."